


Claims

The invention claimed is:

1. A compound having the structure of Formula I:



or pharmaceutically acceptable salts thereof, wherein:

X is a (5- to 14-membered)heteroaryl containing 1-3 heteroatoms;

R¹ is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, oxo, —SF₅, nitro, optionally substituted (C₁-C₆)alkyl, optionally substituted (C₂-C₆)alkenyl, optionally substituted (C₂-C₆)alkynyl, optionally substituted thio(C₁-C₆)alkyl, optionally substituted (C₁-C₆)alkoxy, optionally substituted (C₃-C₈)cycloalkyl, —N(R⁴)(R⁵), —N(R⁴)(C(=O)R⁵), —C(=O)N(R⁴)(R⁵), —O—C(=O)N(R⁴)(R⁵), —C(=O)—R⁴, and —C(=O)—OR⁴;

R^{2a} and R^{2b} at each occurrence, are independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, —SF₅, nitro, optionally substituted (C₁-C₆)alkyl, optionally substituted (C₂-C₆)alkenyl, optionally substituted (C₂-C₆)alkynyl, optionally substituted thio(C₁-C₆)alkyl, optionally substituted (C₁-C₆)alkoxy, optionally substituted (C₁-C₆)alkoxy (C₁-C₆)alkyl, optionally substituted (C₃-C₈)cycloalkyl, optionally substituted phenyl, —N(R⁴)(R⁵), —N(R⁴)(C(=O)R⁵), —C(=O)N(R⁴)(R⁵), —O—C(=O)N(R⁴)(R⁵), —C(=O)—R⁴, and —C(=O)—OR⁴; or R^{2a} and R^{2b} together with the carbon atom(s) to which they are attached form a (C₃-C₈)cycloalkyl or a (4- to 10-membered)heterocycloalkyl, wherein the (C₃-C₈)cycloalkyl and the (4- to 10-membered)heterocycloalkyl are optionally substituted with one to three R⁸;

R^{4a} and R^{4b} are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, oxo, —SF₅, nitro, optionally substituted (C₁-C₆)alkyl, optionally substituted (C₂-C₆)alkenyl, optionally substituted (C₂-C₆)alkynyl, optionally substituted thio(C₁-C₆)alkyl, optionally substituted (C₁-C₆)alkoxy, optionally substituted (C₁-C₆)alkoxy(C₁-C₆)alkyl, optionally substituted (C₃-C₈)cycloalkyl, optionally substituted phenyl, —N(R⁴)(R⁵), —N(R⁴)(C(=O)R⁵), —C(=O)N(R⁴)(R⁵), —O—C(=O)N

(R⁴)(R⁵), —C(=O)—R⁴, and —C(=O)—OR⁴; or R^{4a} and R^{4b} together with the carbon atom to which they are attached form a (C₃-C₈)cycloalkyl, wherein the (C₃-C₈)cycloalkyl is optionally substituted with one to three R⁸;

R^{5a} and R^{5b}, at each occurrence, are independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, oxo, —SF₅, nitro, optionally substituted (C₁-C₆)alkyl, optionally substituted (C₂-C₆)alkenyl, optionally substituted (C₂-C₆)alkynyl, optionally substituted thio(C₁-C₆)alkyl, optionally substituted (C₁-C₆)alkoxy, optionally substituted (C₁-C₆)alkoxy (C₁-C₆)alkyl, optionally substituted (C₃-C₈)cycloalkyl, optionally substituted phenyl, —N(R⁴)(R⁵), (R⁴)(C(=O)R⁵), —C(=O)N(R⁴)(R⁵), —O—C(=O)N(R⁴)(R⁵), —C(=O)—R⁴, and —C(=O)—OR⁴; or R^{5a} and R^{5b} together with the carbon atom to which they are attached form a (C₃-C₈)cycloalkyl, wherein said (C₃-C₈)cycloalkyl is optionally substituted with one to three R⁸;

R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, halogen, cyano, —SF₅, nitro, optionally substituted (C₁-C₆)alkyl, optionally substituted (C₂-C₆)alkenyl, optionally substituted (C₂-C₆)alkynyl, optionally substituted thio(C₁-C₆)alkyl, optionally substituted (C₁-C₆)alkoxy, optionally substituted (C₁-C₆)alkoxy(C₁-C₆)alkyl, optionally substituted (C₃-C₈)cycloalkyl, optionally substituted phenyl, —N(R⁴)(R⁵), —N(R⁴)(C(=O)R⁵), —C(=O)N(R⁴)(R⁵), —O—C(=O)N(R⁴)(R⁵), —C(=O)—R⁴, —C(=O)—OR⁴, and —OR⁹; provided that R⁶ and R⁷ cannot both be hydroxy;

R⁸, at each occurrence, is independently selected from the group consisting of cyano, halogen, hydroxy, —SF₅, nitro, optionally substituted (C₁-C₆)alkyl, optionally substituted (C₁-C₆)alkoxy, and optionally substituted (C₁-C₆)alkoxy(C₁-C₆)alkyl;

R⁹ is selected from the group consisting of hydrogen and optionally substituted (C₁-C₆)alkyl;

y is an integer selected from 1, 2, 3 or 4;

ring B is optionally substituted with one to three R¹⁰, wherein each R¹⁰ is independently selected from the group consisting of halogen, cyano, hydroxy, —SF₅, nitro, optionally substituted (C₁-C₆)alkyl, optionally substituted (C₂-C₆)alkenyl, optionally substituted (C₂-C₆)alkynyl, optionally substituted thio(C₁-C₆)alkyl, optionally substituted (C₁-C₆)alkoxy, optionally substituted (C₃-C₈)cycloalkyl, —N(R⁴)(R⁵), —N(R⁴)(C(=O)R⁵), —C(=O)N(R⁴)(R⁵), —O—C(=O)N(R⁴)(R⁵), —C(=O)—R⁴, and —C(=O)—OR⁴; or two R¹⁰ substituents taken together with the carbon atom(s) to which they are attached form an optionally substituted (C₃-C₈)cycloalkyl;

ring D is optionally substituted with one to four R¹¹, wherein each R¹¹ is independently selected from the group consisting of halogen, cyano, hydroxy, —SF₅, nitro, optionally substituted (C₁-C₆)alkyl, optionally substituted (C₂-C₆)alkenyl, optionally substituted (C₂-C₆)alkynyl, optionally substituted thio(C₁-C₆)alkyl, optionally substituted (C₁-C₆)alkoxy, optionally substituted (C₃-C₈)cycloalkyl, optionally substituted (4- to 6-membered)heterocycloalkyl, —N(R⁴)(R⁵), —N(R⁴)(C(=O)R⁵), —C(=O)N(R⁴)(R⁵), —O—C(=O)N(R⁴)(R⁵), —C(=O)—R⁴, —C(=O)—OR⁴; and

R⁴ and R⁵, at each occurrence, are each independently selected from hydrogen or optionally substituted (C₁-C₆)alkyl;

provided that the compound is not 7-(4-methyl-1H-imidazol-1-yl)-2-{{5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl}methyl}-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, or a pharmaceutically acceptable salt of said compound.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X is represented by:

- i) a (5- to 6-membered)heteroaryl containing 1-3 heteroatoms;
- ii) a (6-membered)heteroaryl containing 1-3 heteroatoms;
- or
- iii) a (5-membered)heteroaryl containing 1-3 heteroatoms.

3. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein X is a (5-membered) heteroaryl selected from the group consisting of triazolyl, imidazolyl, furanyl, thiophenyl, pyrazolyl, isothiazolyl, thiazolyl, isoxazolyl, and oxazolyl.

4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein X is imidazolyl.

5. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein X is triazolyl.

6. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, oxo, $-\text{SF}_5$, nitro, optionally substituted $(\text{C}_1\text{-C}_6)$ alkyl, optionally substituted $(\text{C}_2\text{-C}_6)$ alkenyl, optionally substituted $(\text{C}_2\text{-C}_6)$ alkynyl, optionally substituted thio $(\text{C}_1\text{-C}_6)$ alkyl, optionally substituted $(\text{C}_1\text{-C}_6)$ alkoxy, optionally substituted $(\text{C}_3\text{-C}_8)$ cycloalkyl, $-\text{N}(\text{R}^4)(\text{R}^5)$, $-\text{N}(\text{R}^4)(\text{C}(\text{O})\text{R}^5)$, $-\text{C}(\text{O})\text{N}(\text{R}^4)(\text{R}^5)$, $-\text{O}-\text{C}(\text{O})\text{N}(\text{R}^4)(\text{R}^5)$, $-\text{C}(\text{O})-\text{R}^4$, and $-\text{C}(\text{O})-\text{OR}^4$;

R^{2a} and R^{2b} at each occurrence, are independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, $-\text{SF}_5$, nitro, optionally substituted $(\text{C}_1\text{-C}_6)$ alkyl, optionally substituted $(\text{C}_2\text{-C}_6)$ alkenyl, optionally substituted $(\text{C}_2\text{-C}_6)$ alkynyl, optionally substituted thio $(\text{C}_1\text{-C}_6)$ alkyl, optionally substituted $(\text{C}_1\text{-C}_6)$ alkoxy, optionally substituted $(\text{C}_1\text{-C}_6)$ alkoxy $(\text{C}_1\text{-C}_6)$ alkyl, optionally substituted $(\text{C}_3\text{-C}_8)$ cycloalkyl, optionally substituted phenyl, $-\text{N}(\text{R}^4)(\text{R}^5)$, $-\text{N}(\text{R}^4)(\text{C}(\text{O})\text{R}^5)$, $-\text{C}(\text{O})\text{N}(\text{R}^4)(\text{R}^5)$, $-\text{O}-\text{C}(\text{O})\text{N}(\text{R}^4)(\text{R}^5)$, $-\text{C}(\text{O})-\text{R}^4$, and $-\text{C}(\text{O})-\text{OR}^4$;

R^{4a} and R^{4b} are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, oxo, $-\text{SF}_5$, nitro, optionally substituted $(\text{C}_1\text{-C}_6)$ alkyl, optionally substituted $(\text{C}_2\text{-C}_6)$ alkenyl, optionally substituted $(\text{C}_2\text{-C}_6)$ alkynyl, optionally substituted thio $(\text{C}_1\text{-C}_6)$ alkyl, optionally substituted $(\text{C}_1\text{-C}_6)$ alkoxy, optionally substituted $(\text{C}_1\text{-C}_6)$ alkoxy $(\text{C}_1\text{-C}_6)$ alkyl, optionally substituted $(\text{C}_3\text{-C}_8)$ cycloalkyl, optionally substituted phenyl, $-\text{N}(\text{R}^4)(\text{R}^5)$, $-\text{N}(\text{R}^4)$

$(C(=O)R^5)$, $-C(=O)N(R^4)(R^5)$, $-O-C(=O)N(R^4)(R^5)$, $-C(=O)-R^4$, and $-C(=O)-OR^4$;
 R^{5a} and R^{5b} , at each occurrence, are independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, oxo, $-SF_5$, nitro, optionally substituted (C_1-C_6) alkyl, optionally substituted (C_2-C_6) alkenyl, optionally substituted (C_2-C_6) alkynyl, optionally substituted thio (C_1-C_6) alkyl, optionally substituted (C_1-C_6) alkoxy, optionally substituted (C_1-C_6) alkoxy (C_1-C_6) alkyl, optionally substituted (C_3-C_8) cycloalkyl, optionally substituted phenyl, $-N(R^4)(R^5)$, $-N(R^4)(C(=O)R^5)$, $-C(=O)N(R^4)(R^5)$, $-O-C(=O)N(R^4)(R^5)$, $-C(=O)-R^4$, and $-C(=O)-OR^4$;
 R^6 and R^7 are each independently selected from the group consisting of hydrogen, halogen, cyano, $-SF_5$, nitro, optionally substituted (C_1-C_6) alkyl, optionally substituted (C_2-C_6) alkenyl, optionally substituted (C_2-C_6) alkynyl, optionally substituted thio (C_1-C_6) alkyl, optionally substituted (C_1-C_6) alkoxy, optionally substituted (C_1-C_6) alkoxy (C_1-C_6) alkyl, optionally substituted (C_3-C_8) cycloalkyl, optionally substituted phenyl, $-N(R^4)(R^5)$, $-N(R^4)(C(=O)R^5)$, $-C(=O)N(R^4)(R^5)$, $-O-C(=O)N(R^4)(R^5)$, $-C(=O)-R^4$, $-C(=O)-OR^4$, and $-OR^9$; provided that R^6 and R^7 cannot both be hydroxy;
 R^9 is selected from the group consisting of hydrogen and optionally substituted (C_1-C_6) alkyl;
 y is an integer selected from 1, 2, 3 or 4;
ring B is optionally substituted with one to three R^{10} , wherein each R^{10} is independently selected from the group consisting of halogen, cyano, hydroxy, $-SF_5$, nitro, optionally substituted (C_1-C_6) alkyl, optionally substituted (C_2-C_6) alkenyl, optionally substituted (C_2-C_6) alkynyl, optionally substituted thio (C_1-C_6) alkyl, optionally substituted (C_1-C_6) alkoxy, optionally substituted (C_3-C_8) cycloalkyl, $-N(R^4)(R^5)$, $-N(R^4)(C(=O)R^5)$, $-C(=O)N(R^4)(R^5)$, $-O-C(=O)N(R^4)(R^5)$, $-C(=O)-R^4$, $-C(=O)-OR^4$;

ring D is optionally substituted with one to four R^{11} , wherein each R^{11} is independently selected from the group consisting of halogen, cyano, hydroxy, $-\text{SF}_5$, nitro, optionally substituted $(\text{C}_1\text{-C}_6)\text{alkyl}$, optionally substituted $(\text{C}_2\text{-C}_6)\text{alkenyl}$, optionally substituted $(\text{C}_2\text{-C}_6)\text{alkynyl}$, optionally substituted thio $(\text{C}_1\text{-C}_6)\text{alkyl}$, optionally substituted $(\text{C}_1\text{-C}_6)\text{alkoxy}$, optionally substituted $(\text{C}_3\text{-C}_8)\text{cycloalkyl}$, optionally substituted (4- to 6-membered)heterocycloalkyl; $-\text{N}(\text{R}^4)(\text{R}^5)$, $-\text{N}(\text{R}^4)(\text{C}(\text{=O})\text{R}^5)$, $-\text{C}(\text{=O})\text{N}(\text{R}^4)(\text{R}^5)$, $-\text{O}-\text{C}(\text{=O})\text{N}(\text{R}^4)(\text{R}^5)$, $-\text{C}(\text{=O})-\text{R}^4$, $-\text{C}(\text{=O})-\text{OR}^4$; and R^4 and R^5 , at each occurrence, are each independently selected from hydrogen or optionally substituted $(\text{C}_1\text{-C}_6)\text{alkyl}$.

7. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, optionally substituted $(\text{C}_1\text{-C}_6)\text{alkyl}$, and optionally substituted $(\text{C}_1\text{-C}_6)\text{alkoxy}$; wherein the $(\text{C}_1\text{-C}_6)\text{alkyl}$ and $(\text{C}_1\text{-C}_6)\text{alkoxy}$ are optionally substituted with one to three substituents selected from halogen, oxo, cyano, hydroxy, or $-\text{SF}_5$;

R^{2a} and R^{2b} are each independently selected from hydrogen, halogen, cyano, hydroxy or optionally substituted $(\text{C}_1\text{-C}_6)\text{alkyl}$;

R^{4a} , R^{4b} , R^{5a} and R^{5b} are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, oxo, $-\text{SF}_5$, optionally substituted $(\text{C}_1\text{-C}_6)\text{alkyl}$, and optionally substituted $(\text{C}_1\text{-C}_6)\text{alkoxy}$,

wherein the $(\text{C}_1\text{-C}_6)\text{alkyl}$ and $(\text{C}_1\text{-C}_6)\text{alkoxy}$ are optionally substituted with one to three substituents selected from halogen, oxo, cyano, hydroxy, or $-\text{SF}_5$;

R^6 and R^7 are each independently selected from the group consisting of hydrogen, cyano, halogen, $-\text{SF}_5$, optionally substituted $(\text{C}_1\text{-C}_6)\text{alkyl}$, and optionally substituted $(\text{C}_1\text{-C}_6)\text{alkoxy}$, wherein the $(\text{C}_1\text{-C}_6)\text{alkyl}$ and $(\text{C}_1\text{-C}_6)\text{alkoxy}$ are optionally substituted with one to three substituents selected from halogen, oxo, cyano, hydroxy, or $-\text{SF}_5$;

y is 1,

ring B is optionally substituted with one to two R^{10} , wherein each R^{10} is independently selected from halogen, cyano, hydroxy, $-\text{SF}_5$, optionally substituted $(\text{C}_1\text{-C}_6)$ alkyl, and optionally substituted $(\text{C}_1\text{-C}_6)$ alkoxy, wherein the $(\text{C}_1\text{-C}_6)$ alkyl and $(\text{C}_1\text{-C}_6)$ alkoxy are optionally substituted with one to three substituents selected from halogen, oxo, cyano, hydroxy, or $-\text{SF}_5$; and

ring D is optionally substituted with one to three R^{11} , wherein each R^{11} is independently selected from the group consisting of halogen, cyano, hydroxy, optionally substituted $(\text{C}_1\text{-C}_6)$ alkyl, optionally substituted $(\text{C}_1\text{-C}_6)$ alkoxy, $-\text{SF}_5$, $-\text{N}(\text{R}^4)(\text{R}^5)$, nitro, and optionally substituted $(\text{C}_3\text{-C}_8)$ cycloalkyl, wherein the $(\text{C}_1\text{-C}_6)$ alkyl, $(\text{C}_1\text{-C}_6)$ alkoxy, and $(\text{C}_3\text{-C}_8)$ cycloalkyl are optionally substituted with one to three substituents independently selected from halogen, cyano, hydroxy, $-\text{SF}_5$, and optionally substituted $(\text{C}_1\text{-C}_6)$ alkyl, wherein R^4 and R^5 are each independently selected from hydrogen or optionally substituted $(\text{C}_1\text{-C}_6)$ alkyl.

8. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is an optionally substituted $(\text{C}_1\text{-C}_6)$ alkyl, wherein the $(\text{C}_1\text{-C}_6)$ alkyl is substituted with one to three substituents selected from halogen, oxo, cyano, hydroxy, or $-\text{SF}_5$; and

R^{2a} , R^{2b} , R^{4a} , R^{4b} , R^{5a} and R^{5b} are each independently

i) hydrogen; or

ii) optionally substituted $(\text{C}_1\text{-C}_6)$ alkyl, wherein the $(\text{C}_1\text{-C}_6)$ alkyl is substituted with one to three substituents selected from halogen, oxo, cyano, hydroxy, or $-\text{SF}_5$.


9. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein R^1 is methyl; and R^{2a} , R^{2b} , R^{4a} , R^{4b} , R^{5a} and R^{5b} are each independently hydrogen.

10. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein R^1 is methyl; R^{2a} , R^{2b} , R^{5a} and R^{5b} are each independently hydrogen; and one of R^{4a} and R^{4b} is hydrogen and the other is methyl.

11. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein R^1 is methyl; one of R^{2a} and R^{2b} is hydrogen and the other is methyl; R^{4a} , R^{4b} , R^{5a} and R^{5b} are each independently hydrogen.

12. A compound having the structure of Formula II:

Formula II



or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, optionally substituted (C_1 - C_6)alkyl, and optionally substituted (C_1 - C_6)alkoxy; wherein the (C_1 - C_6)alkyl and (C_1 - C_6)alkoxy are optionally substituted with one to three substituents selected from halogen, oxo, cyano, hydroxy, or $-SF_5$;
 R^{2a} , R^{2b} , R^{4a} , R^{4b} , R^{5a} and R^{5b} are each independently selected from hydrogen, halogen, cyano, hydroxy or optionally substituted (C_1 - C_6)alkyl;

ring B is optionally substituted with one to two R^{10} , wherein each R^{10} is independently selected from halogen or optionally substituted (C_1-C_6) alkyl; and

ring D is optionally substituted with one to three R^{11} , wherein each R^{11} is independently selected from halogen, optionally substituted (C_1-C_6) alkyl, and optionally substituted (C_1-C_6) alkoxy;

provided that the compound is not 7-(4-methyl-1H-imidazol-1-yl)-2- $\{[5-(\text{trifluoromethyl})-1,1a\text{-dihydro-}6b\text{H-cyclopropa}[b][1]\text{benzofuran-}6b\text{-yl}]methyl\}$ -3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, or a pharmaceutically acceptable salt of said compound.

13. The compound according to claim 12, wherein:

R^1 is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, (C_1-C_6) alkyl, and (C_1-C_6) alkoxy; wherein the (C_1-C_6) alkyl and (C_1-C_6) alkoxy are optionally substituted with one to three fluoro atoms;

R^{2a} , R^{2b} , R^{4a} , R^{4b} , R^{5a} and R^{5b} are each independently selected from hydrogen or (C_1-C_6) alkyl, wherein the (C_1-C_6) alkyl is methyl;

ring B is optionally substituted with one to two R^{10} , wherein each R^{10} is selected from:

- i) halogen selected from fluoro or chloro, or
- ii) (C_1-C_6) alkyl, wherein the (C_1-C_6) alkyl is methyl; and


ring D is optionally substituted with one to three R^{11} , wherein each R^{11} is selected from:

- i) halogen selected from fluoro or chloro;
- ii) optionally substituted (C_1-C_6) alkyl selected from the group consisting of fluoromethyl, difluoromethyl, and trifluoromethyl; and
- iii) optionally substituted (C_1-C_6) alkoxy, wherein the optionally substituted (C_1-C_6) alkoxy is selected from the group consisting of fluoromethoxy, difluoromethoxy, trifluoromethoxy.

14. The compound according to claim 12, wherein R^1 is a (C_1-C_6) alkyl wherein the alkyl is methyl.

15. A compound having the structure of Formula III:

Formula III



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, optionally substituted (C₁-C₆)alkyl, and optionally substituted (C₁-C₆)alkoxy; wherein the (C₁-C₆)alkyl and (C₁-C₆)alkoxy are optionally substituted with one to three substituents selected from halogen, oxo, cyano, hydroxy, or —SF₅;

R^{2a}, R^{2b}, R^{4a}, R^{4b}, R^{5a} and R^{5b} are each independently selected from hydrogen, halogen, cyano, hydroxy or optionally substituted (C₁-C₆)alkyl;

ring B is optionally substituted with one to two R¹⁰, wherein each R¹⁰ is independently selected from halogen or optionally substituted (C₁-C₆)alkyl; and

ring D is optionally substituted with one to three R¹¹, wherein each R¹¹ is independently selected from halogen, optionally substituted (C₁-C₆)alkyl, and optionally substituted (C₁-C₆)alkoxy.

16. The compound according to claim 15, wherein:

R¹ is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, (C₁-C₆)alkyl, and (C₁-C₆)alkoxy; wherein the (C₁-C₆)alkyl and (C₁-C₆)alkoxy are optionally substituted with one to three fluoro atoms;

R^{2a}, R^{2b}, R^{4a}, R^{4b}, R^{5a} and R^{5b} are each independently selected from hydrogen or (C₁-C₆)alkyl, wherein the (C₁-C₆)alkyl is methyl;

ring B is optionally substituted with one to two R¹⁰, wherein each R¹⁰ is selected from:

- i) halogen selected from fluoro or chloro, or
- ii) (C₁-C₆)alkyl, wherein the (C₁-C₆)alkyl is methyl; and

ring D is optionally substituted with one to three R¹¹, wherein each R¹¹ is selected from:

- i) halogen selected from fluoro or chloro;
- ii) optionally substituted (C₁-C₆)alkyl selected from the group consisting of fluoromethyl, difluoromethyl, and trifluoromethyl; and
- iii) optionally substituted (C₁-C₆)alkoxy, wherein the optionally substituted (C₁-C₆)alkoxy is selected from the group consisting of fluoromethoxy, difluoromethoxy, and trifluoromethoxy.

17. A compound selected from the group consisting of:

7-(4-methyl-1H-imidazol-1-yl)-2-{[1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;

7-(4-methyl-1H-imidazol-1-yl)-2-{[(1aS,6bS)-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;

7-(4-methyl-1H-imidazol-1-yl)-2-{[(1aR,6bR)-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;

2-{[3-fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;

2-{[(1aS,6bS)-3-fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;

2-{[(1aR,6bR)-3-fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;

- 2-{{[4-fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aS,6bS)-4-fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aR,6bR)-4-fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[4-fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(3-methyl-1H-1,2,4-triazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aS,6bS)-4-fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(3-methyl-1H-1,2,4-triazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aR,6bR)-4-fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(3-methyl-1H-1,2,4-triazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aS,6bS)-4-chloro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aR,6bR)-4-chloro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aS,6bS)-5-(difluoromethoxy)-4-fluoro-1a-methyl-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;

- 2-{{[(1aR,6bR)-5-(difluoromethoxy)-4-fluoro-1a-methyl-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aS,6bS)-4-fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-[4-(hydroxymethyl)-1H-imidazol-1-yl]-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 7-(4-methyl-1H-imidazol-1-yl)-2-{{[(1aS,6bS)-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 7-(4-methyl-1H-imidazol-1-yl)-2-{{[(1aR,6bR)-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aS,6bS)-4-fluoro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aR,6bR)-4-fluoro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aS,6bS)-3-fluoro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aR,6bR)-3-fluoro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aS,6bS)-3-chloro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione;
- 2-{{[(1aR,6bR)-3-chloro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl]methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione; or a pharmaceutically acceptable salt thereof.

18. 2-{[(1aS,6bS)-4-Fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl)methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

19. 2-{[(1aR,6bR)-4-Fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl)methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

20. 2-{[(1aS,6bS)-3-Fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl)methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

21. 2-{[(1aR,6bR)-3-Fluoro-1a-methyl-5-(trifluoromethoxy)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl)methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

22. 2-{[(1aS,6bS)-4-Chloro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl)methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

23. 2-{[(1aR,6bR)-4-Chloro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b][1]benzofuran-6b-yl)methyl}-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

24. 2-(((1aS,6bS)-4-fluoro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b]benzofuran-6b-yl)methyl)-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

25. 2-(((1aR,6bR)-4-fluoro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b]benzofuran-6b-yl)methyl)-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

26. 2-(((1aS,6bS)-3-fluoro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b]benzofuran-6b-yl)methyl)-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.

27. 2-(((1aR,6bR)-3-fluoro-1a-methyl-5-(trifluoromethyl)-1,1a-dihydro-6bH-cyclopropa[b]benzofuran-6b-yl)methyl)-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione, or a pharmaceutically acceptable salt thereof.